Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

OBJECTIVE: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. METHODS: RAPID-axSpA was a phase 3 randomized trial, double blind and pl...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Dougados, Maxime, Landewé, Robert, Sieper, Joachim, Maksymowych, Walter P., Rudwaleit, Martin, Van den Bosch, Filip, Braun, Jürgen, Mease, Philip J., Kivitz, Alan J., Walsh, Jessica, Davies, Owen, Bauer, Lars, Hoepken, Bengt, Peterson, Luke, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850296/
https://www.ncbi.nlm.nih.gov/pubmed/28498975
http://dx.doi.org/10.1093/rheumatology/kex174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850296/
https://www.ncbi.nlm.nih.gov/pubmed/28498975
http://dx.doi.org/10.1093/rheumatology/kex174

Ejemplares similares